Kaida BioPharma Launches Social Media Channels

Procaps Issues Shareholder Letter Update

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO

Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia

Tilray Medical Launches Redecan Cannabis Brand in Australia

Nicox Announces Approval of ZERVIATE in China

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer

Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024

ADIA Nutrition Stakes Claim in $6.7B Industry with Strategic Trademark Expansion

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Elicio Therapeutics Reports Inducement Grants

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

Sanofi: Information concerning the total number of voting rights and shares - August 2024

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

Virbac: erratum short Press release Capital reduction_September 13, 2024

SRx Health Insiders Purchase Shares of Better Choice in the Open Market

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer

Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle invasive bladder cancer

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer

RYBREVANT®▼ (amivantamab) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer

RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Company Statement on FDA Advisory Committee Meeting

Virbac : Half-yearly financial report 2024

Virbac : Public release of the Half-Year Financial Report at 30 June 2024.

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Virbac : the board of directors announces a capital reduction through cancellation of treasury shares

Virbac: Information on the departure of Sébastien Huron

Virbac 2024 half-year results

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution

FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Tilray Brands Completes Acquisition of Atwater Brewery From Molson Coors Beverage Company

Johnson & Johnson seeks first EU approval of nipocalimab to treat a broad population of patients living with antibody-positive generalised myasthenia gravis

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Breckenridge Brewery Unveils Oktoberfest Brew and Hosts 28th Annual Oktoberfest Festival: A Weekend of Live Music, Traditional German Cuisine, and Tasty Brews in Breckenridge, Colorado

Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer